Immunovant Inc
(NAS:IMVT)
$
26
-0.6 (-2.26%)
Market Cap: 3.80 Bil
Enterprise Value: 3.16 Bil
PE Ratio: 0
PB Ratio: 6.13
GF Score: 42/100 - Immunovant Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Immunovant Inc To Discuss Portfolio Update Call TranscriptNov 28, 2023
- Immunovant Inc Initial Phase 1 Results Call TranscriptSep 26, 2023
- Immunovant Inc Fireside Chat Hosted by LifeSci Capital TranscriptDec 08, 2022
- Immunovant Inc Investor Day TranscriptSep 28, 2022
- Immunovant Inc To Discuss On Two New Indications For Batoclimab Call TranscriptSep 07, 2022
- Q4 2022 Immunovant Inc Earnings Call TranscriptJun 08, 2022$3.92 (-8.20%)Earnings
- Immunovant Inc at UBS Global Healthcare Conference TranscriptMay 23, 2022
- Immunovant Inc To Host R&D Day (Virtual) TranscriptMar 30, 2022
- Immunovant Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Immunovant Inc To Discuss Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 Call TranscriptJan 05, 2022
- Immunovant Inc at Stifel Healthcare Conference (Virtual) TranscriptNov 17, 2021
- Immunovant Inc at Roivant R&D Day (Virtual) TranscriptSep 28, 2021
- Q1 2022 Immunovant Inc Earnings Call TranscriptAug 09, 2021$7.78 (+0.39%)Earnings
- Q4 2021 Immunovant Inc Earnings Call TranscriptJun 01, 2021$9.4 (-37.99%)Earnings
- Immunovant, Inc. - Special Call TranscriptFeb 02, 2021
- Immunovant Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 12, 2020
- Immunovant, Inc. - Special Call TranscriptAug 25, 2020
- Immunovant Inc Annual Shareholders Meeting TranscriptAug 19, 2020
- Immunovant Inc Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a Trial Of IMVT-1401 In Thyroid Eye Disease, And Provides Corporate Update TranscriptMar 30, 2020
Immunovant Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 12, 2020 / 03:15PM GMT
Release Date Price:
$49.14
(+0.02%)
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst
© -
Everyone, welcome to the last day of our healthcare conference at Crédit Suisse. My name is Tiago Fauth, mid-cap biotech analyst here at Crédit Suisse. And I'm joined today by the Immunovant team. They're going to do a presentation. Feel free to e-mail me any questions, and I'll try to work those in towards the end.
But for now, that's it, I think. Pete, you can take it away.
Peter Salzmann
Immunovant, Inc. - CEO & Director
Super. Thanks, Tiago. Let me just share my screen here. You see that, okay?
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst
© -
Yes.
Peter Salzmann
Immunovant, Inc. - CEO & Director
Excellent. So I just want to briefly touch on our safe harbor presentation statement. This is on our website, this entire presentation is on our website, and I will be making some forward-looking
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)